Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06568614 · ClinicalTrials.gov registry record · Phase 1
An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors
A Phase 1 study of Advanced or Metastatic MTAP-deleted Solid Tumors, sponsored by BeOne Medicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
- 20
- Study locations
NCT06568614: Recruiting Phase 1 study of Advanced or Metastatic MTAP-deleted Solid Tumors, sponsored by BeOne Medicines.
NCT06568614 is a Phase 1 study of Advanced or Metastatic MTAP-deleted Solid Tumors that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 140 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (133% higher). The trial reports 20 study locations across 18 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06568614, a Phase 1 study of Advanced or Metastatic MTAP-deleted Solid Tumors, is actively recruiting participants, sponsored by BeOne Medicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being done to learn more about a new drug called BG-89894 (previously known as SYH2039). Researchers want to see if the drug is safe, how well people can tolerate it, how it moves through the body, and whether it shows any early signs of helping to treat cancer. The information gathered may help guide how future studies are designed. The entire study is expected to last about four years. People who join the study may receive treatment for around six months and will be followed for about 12 months after their treatment ends. The study plans to enroll participants over a three-year period.
Primary Outcome
Number of participants experiencing adverse events and serious adverse events as determined per Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0), including findings from physical examinations, electrocardiograms (ECGs), laboratory assessments, and that meet protocol-defined dose-limiting toxicity (DLT) criteria.
Conditions Studied
Interventions
- DRUG BG-89894
Study Locations (20)
Beijing Municipality
- Cancer Hospital Chinese Academy of Medical Sciences - Beijing
- Beijing Cancer Hospital - Beijing
- Beijing Tsinghua Changgung Hospital - Beijing
Maryland
- Sidney Kimmel Comprehensive Cancer At Johns Hopkins - Baltimore
Missouri
- Washington University School of Medicine - St Louis
New York
- Columbia University Irving Medical Center - New York
Virginia
- Next Virginia - Fairfax
New South Wales
- Blacktown Cancer and Haematology Centre - Blacktown
South Australia
- Cancer Research South Australia - Adelaide
Victoria
- St Vincents Hospital - Fitzroy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2024-10-12 |
| Est. Completion | 2028-12-30 |
| Phase | Phase 1 |
What NCT06568614 shows while recruiting
NCT06568614 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (133% higher).
The record links to 1 condition, with Advanced or Metastatic MTAP-deleted Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which BG-89894 is the first listed.
NCT06568614 names 20 study sites across 18 states, led by Beijing Municipality, Maryland, Missouri.
Frequently Asked Questions
What is clinical trial NCT06568614 about?
NCT06568614 is a clinical study titled "An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors". This study is being done to learn more about a new drug called BG-89894 (previously known as SYH2039). Researchers want to see if the drug is safe, how well people can tolerate it, how it moves through the body, and whether it shows any early signs of helping to treat cancer. The information gathere...
What is the current status of trial NCT06568614?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2024-10-12. Estimated completion is 2028-12-30.
What conditions does trial NCT06568614 study?
This clinical trial studies the following conditions: Advanced or Metastatic MTAP-deleted Solid Tumors.
What interventions are being tested in trial NCT06568614?
The interventions under investigation include: BG-89894 (DRUG).
Who is sponsoring clinical trial NCT06568614?
This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06568614 being conducted?
This trial has 20 study locations across Maryland, Missouri, New York, Virginia, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06568614's enrollment target sits among peer trials
140 403rd of 2000 higher than 1,583 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI